Navigation Links
Inovio Pharmaceuticals to Hold Investor Conference Call to Discuss Partnership with Roche
Date:9/10/2013

BLUE BELL, Pa., Sept. 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) will hold a conference call with investors this morning, Tuesday September 10, at 8:00 a.m. (ET) to discuss its partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) which the companies announced today.

The audio presentation will be broadcast online at http://www.investorcalendar.com/IC/CEPage.asp?ID=171545. Investors can also access the presentation through the "Webcast" tab on Inovio's home page at www.inovio.com.  This is a listen-only event but will include a live Q&A with analysts. An archived version of the webcast will be available for 90 days beginning two hours after the call.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target breast and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Roche entered into an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies targeting prostate cancer and hepatitis B. Other partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is av
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
2. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
3. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
6. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
7. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
8. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
9. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
10. EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
11. Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Clintrax Global, Inc., a ... Raleigh, NC , recently announced ... Vice President of Administration. As ... corporate processes, including their alignment with company objectives ... worked as an HR executive, specializing in needs ...
(Date:8/20/2014)... PLANTATION, Fla. , Aug. 20, 2014 /PRNewswire/ ... it will host a conference call to provide ... 26, 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 ... number: 9126599 Live web cast: www.neurotropebioscience.com , under ... three hours after completion through September 2, 2014 ...
(Date:8/20/2014)... 20, 2014 The 6th Annual ... held on October 29-30 in San Francisco, CA. This ... and government researchers and clinicians focused on addressing and ... , In the twelve years since the sequencing of ... been introduced with pharmacogenetic information in the label and ...
(Date:8/20/2014)... August 20, 2014 WriteResult®, a leading ... that it has expanded its myPROpad™ ePRO tablet with ... one of the most widely used and well-respected ... health status. The EQ-5D is used during clinical trials ... measure that can be used to demonstrate Health-Related Quality ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2
... July 23 /PRNewswire-FirstCall/ - Roche,(SWX: ROG) and ARIUS ... have signed a definitive agreement for Roche to ... of approximately C$191 million. ARIUS is,the developer of ... and selects antibodies based on their functional,ability to ...
... ALTO, Calif., July 22 CV Therapeutics,Inc. (Nasdaq: ... quarter,financial results for 2008 after the market closes on ... call at 5:00 p.m. EDT,2:00 p.m. PDT, on the ... log on to the Company,s website at, http://www.cvt.com ...
... N.J., July 22 The Board of,Directors of BD ... declared a,quarterly dividend of 28.5 cents per common share. ... holders of record on September 9, 2008.,The indicated annual ... BD is a leading global medical technology company ...
Cached Biology Technology:Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 2Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 3Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 4CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008 2
(Date:8/19/2014)... German . ... a large amount of electricity is to be produced with ... to be stored during productive periods so that these fluctuations ... from adequate for the purpose. Science and industry are therefore ... battery systems that used to be too expensive or unsophisticated ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
(Date:8/19/2014)... New measurements from fish purchased at retail seafood ... to which mislabeling can expose consumers to unexpectedly ... Fishery stock "substitutions"which falsely present a fish of ... originare the most dangerous mislabeling offense, according to ... scientists. , "Accurate labeling of seafood is essential ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... Canadian researcher working in the U.K. says doctors, authors ... claiming that hyperactivity as we understand it today has ... that notion wrong, it misleads patients, their parents and ... finishing up his PhD at the Centre for Medical ...
... embarrassing, but a new study suggests that it might ... interviewed more than three thousand men - all pairs ... - about the first time they had sex. Many ... from erectile dysfunction and premature ejaculation at their first ...
... for proposals, projects focus on either the development of ... and genomics. The Swiss National Science Foundation (SNSF) approved ... 47 research groups from both Swiss Federal Institutes of ... from the Universities of Basel, Lausanne, Geneva and Zurich. ...
Cached Biology News:History of hyperactivity off-base, says researcher 2Swiss Initiative in Systems Biology launches new projects 2
Wnt-1 (G-19)...
... G4-1, Affinity-Purified Polyclonal IgY Antibodies ... phosphatase subunit gene g4-1 Protein ... query: 8923600 Genbank Definition: ... likely ortholog of mouse phosphatase subunit gene ...
HSV-1 gE Envelope Protein (9H3)...
... C-terminal reactive. Cross-reacts fully with GLP-1(1-36) ... with the unamidated forms GLP-1(7-37) and ... as hGLP-2, glucagon, hGIP and VIP.,SPECIES ... identical in all mammalian species studied ...
Biology Products: